Last Update 22 Feb 26

Fair value Increased 8.09%

ERF: Updated Earnings Assumptions And Testing Expansion Will Shape Future Returns

Analysts have lifted their fair value estimate for Eurofins Scientific from about €66.34 to €71.71. This reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E after recent price target increases, such as the €10.20 raise cited in Street research.

Analyst Commentary

Bullish Takeaways

Bullish analysts point to the raised price target of €10.20 as support for the higher fair value estimate of €71.71, suggesting the updated assumptions on discount rates, revenue, margins and future P/E are more aligned with current expectations.
The higher target is viewed as a sign that earnings power and cash flow potential may justify a stronger valuation multiple compared with the prior fair value of about €66.34.
Positive commentary around the new target implies confidence in Eurofins Scientific's ability to execute against its revenue and profitability assumptions that feed into discounted cash flow work.
Some bullish analysts see scope for the current market price to move closer to the refreshed fair value range if the company delivers in line with the earnings and margin profile used in recent models.

Bearish Takeaways

Bearish analysts may view the higher fair value and €10.20 target lift as relatively modest, suggesting limited valuation upside if the shares already trade near the updated estimates.
The reliance on adjusted assumptions for discount rates, revenue growth and margins leaves room for concern if actual business trends differ from the inputs used in the latest models.
Some cautious views focus on the implied future P/E embedded in the new fair value, questioning whether the earnings trajectory will support that multiple over time.
There is also scepticism that further target increases would require stronger visibility on execution and profitability than what is currently reflected in available research commentary.

What's in the News

Eurofins Viracor BioPharma Services expanded its bioanalytical testing offering with GLP and GCP aligned services, following the integration of Eurofins Pharma Bioanalytics Services into an eleven acre Lenexa, Kansas facility. This brings more than two decades of experience in pharmacokinetics, immunogenicity and biomarker testing under one unit (Key Developments).
The company reported completion of a share buyback tranche, repurchasing 1,496,185 shares from July 1, 2025 to December 31, 2025 for €78.16m, and a total of 3,376,185 shares for €184.14m under the buyback first announced on April 25, 2025 (Key Developments).
The Board of Eurofins Scientific SE intends to propose an annual dividend of €0.72 per share at the April 23, 2026 AGM. This is described as a 20% year on year increase and a split adjusted 27% compound annual growth rate in the dividend per share since the first dividend for 2007 (Key Developments).
Eurofins CDMO Alphora launched an AI powered software platform for high throughput salt and co crystal screening. The platform aims to cut trial and error work, shorten development timelines and lower screening costs for APIs and intermediates in solid state screening programs (Key Developments).
Eurofins Consumer Product Testing Vietnam moved to a new 7,000 sq. m laboratory in Ho Chi Minh City, more than doubling prior floor space. The company cited Vietnam's growing role in global manufacturing and sustained business growth in the region (Key Developments).

Valuation Changes

Fair Value moved from about €66.34 to about €71.71, a rise of roughly 8%.
Discount Rate increased slightly from about 6.87% to about 7.14%.
Revenue Growth was adjusted slightly lower from about 6.46% to about 6.22%.
Net Profit Margin was lifted from about 9.03% to about 9.77%.
Future P/E was raised from about 15.92x to about 18.27x.

3 views

Key Takeaways

Investments in automation, digitalization, and acquisitions will enhance efficiency, productivity, and margins, while unlocking new growth opportunities.
Heightened regulatory standards and demographic trends are supporting stable, resilient demand across core testing and diagnostics services.
Structural challenges in key segments, integration risks from acquisitions, high capital expenditure, limited pricing power, and aggressive expansion strategy threaten margins, growth, and profitability.

Catalysts

About Eurofins Scientific

Provides various analytical testing and laboratory services worldwide.What are the underlying business or industry changes driving this perspective?

The company's significant investments in automation, digitalization, and its hub-and-spoke laboratory infrastructure are expected to materially improve operating efficiency and scalability by 2027. These measures should drive enhanced net margins and earnings growth as operational costs decrease and productivity improves.
Eurofins is benefitting from increasing global regulatory standards in food, environmental, and pharmaceutical testing, supporting structurally higher and more resilient demand for its core services. This underpins a stable and expanding revenue base, which the market may be undervaluing given current pricing.
The ongoing wave of aging populations and the rise of chronic diseases worldwide is leading to robust long-term demand for diagnostics and pharmaceutical R&D, areas where Eurofins' specialized services are positioned to capture incremental growth and revenue acceleration in the coming years.
Strategic acquisitions in targeted niches-often at favorable valuations-are expected to unlock cross-selling synergies and margin uplift following integration, particularly as underperforming acquired assets (like SYNLAB Spain) are turned around by 2027, driving both revenue growth and higher group margins.
The company anticipates a normalization and rebound in weaker verticals such as biopharma and certain genomics segments, where temporary headwinds and restructuring are currently weighing down results; the removal of these one-off drags provides a clear pathway for both renewed revenue growth and margin expansion.

Eurofins Scientific Earnings and Revenue Growth

Eurofins Scientific Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Eurofins Scientific's revenue will grow by 7.1% annually over the next 3 years.
Analysts assume that profit margins will increase from 5.3% today to 8.5% in 3 years time.
Analysts expect earnings to reach €745.8 million (and earnings per share of €3.94) by about September 2028, up from €380.9 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €828 million in earnings, and the most bearish expecting €610 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 15.7x on those 2028 earnings, down from 29.3x today. This future PE is lower than the current PE for the GB Life Sciences industry at 29.3x.
Analysts expect the number of shares outstanding to decline by 4.76% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.23%, as per the Simply Wall St company report.

Eurofins Scientific Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Eurofins continues to experience structural challenges in biopharma and genomics, with certain segments (discovery/genomics and ancillaries) showing negative growth and being impacted by cuts in academic and research budgets (especially in the US); this creates a drag on overall revenue growth and makes the group's medium-term organic growth targets more difficult to achieve if not reversed.
The acquisition and integration of loss-making businesses such as SYNLAB Spain is currently dilutive to group margins (20bps H1, expected 60bps for FY), and restructuring costs, duplication, and operational inefficiencies pose further risk to net margins and overall earnings if synergy extraction does not materialize as planned.
Eurofins' heavy capital expenditure (notably on real estate and digitalization) is absorbing significant cash flow, and if these investments fail to yield expected efficiency or revenue gains by 2027, this could depress free cash flow and constrain further shareholder returns (such as buybacks or increased dividends).
Pricing power is not fully embedded across all verticals; while inflation is assumed in long-term growth targets, there is still limited visibility and capability to pass on cost increases systematically, especially with long-term contracts-this may hinder margin expansion and earnings if inflation remains elevated or customer bargaining power consolidates.
The group's aggressive acquisition-driven growth strategy, coupled with ongoing site rationalization and the need to integrate diverse IT and operational systems, increases risks of execution missteps, integration delays, or cultural challenges, which could negatively impact organic growth, operational efficiency, and ultimately, profitability over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €63.931 for Eurofins Scientific based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €95.0, and the most bearish reporting a price target of just €46.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be €8.8 billion, earnings will come to €745.8 million, and it would be trading on a PE ratio of 15.7x, assuming you use a discount rate of 6.2%.
Given the current share price of €62.86, the analyst price target of €63.93 is 1.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Eurofins Scientific?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Digitalization And Automation Will Unlock Future Diagnostics Potential